External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients.

ABSTRACT:

Background and purpose

The S₂TOP-BLEED score may help to identify patients at high risk of bleeding on antiplatelet drugs after a transient ischemic attack or ischemic stroke. The score was derived on trial populations, and its performance in a real-world setting is unknown. We aimed to externally validate the S₂TOP-BLEED score for major bleeding in a population-based cohort and to compare its performance with other risk scores for bleeding.

Methods

We studied risk of bleeding in 2072 patients with a transient ischemic attack or ischemic stroke on antiplatelet agents in the population-based OXVASC (Oxford Vascular Study) according to 3 scores: S₂TOP-BLEED, REACH, and Intracranial-B₂LEED₃S. Performance was assessed with C

SUBMITTER: Hilkens NA 

PROVIDER: S-EPMC5839707 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature